VM-A 2011 Viral Markers
|
|
|
- Maria O’Connor’
- 5 years ago
- Views:
Transcription
1 EVALUATION VM-A 2011 Viral Markers INSTITUTION: ATTENTION: CAP NUMBER: Kit# 1 KIT INFORMATION: Kit ID: /3/2011 2/8/2011 Next Mailing Date: 9/2011 COPIED TO: LAP CAP LEGEND: Exception Reason Codes appearing in this evaluation: <NONE> Reviewed By Date Page 1 of 4
2 VM-A 2011 Viral Markers Test Method Specimen Your Result Intended Response Your Grade HBsAg FLUORESCENT EIA VM /3/2011 2/8/2011 VM1-02 VM1-03 VM1-04 VM1-05 Anti-HBs FLUORESCENT EIA VM1-01 VM1-02 VM1-03 VM1-04 VM1-05 Page 2 of 4
3 VM-A 2011 Viral Markers Test Method Specimen Your Result Intended Response Your Grade Anti-HIV 1/2 RECOMBINANT EIA VM /3/2011 2/8/2011 VM1-02 VM1-03 VM1-04 VM1-05 Anti-HCV ABBOTT VM1-01 VM1-02 VM1-03 VM1-04 VM1-05 Page 3 of 4
4 VM-A 2011 Viral Markers /3/2011 2/8/2011 CAP #: Regulated Analyte Test Event Score % CAP Subspecialty : General Immunology Test Event Score % Test Event Score % Current Event Cumulative CLIA Performance '88 Performance Interpretation Interpretation Alpha-1-Antitrypsin S-B 5 / S-C Alpha-Fetoprotein K-B 5 / K-C Antinuclear Antibody S-B 5 / S-C Antistreptolysin O S-B 5 / S-C Anti-HIV VM-B 5 / VM-C VM-A Satisfactory Complement C3 S-B 4 / 5 80 S-C 0/ 5 0 <4> Complement C4 S-B 5 / S-C 0/ 5 0 <4> Hepatitis (HBsAg) VM-B 5 / VM-C VM-A Satisfactory IgA S-B 5 / S-C 4/ 5 80 IgG S-B 5 / S-C IgE S-B 5 / S-C IgM S-B 5 / S-C Rheumatoid Factor S-B 4 / 5 80 S-C Successful Successful General Immunology 63/ / / Satisfactory Successful <4> Scorecard performance pending future evaluation or may not be applicable due to discontinued testing or use of a waived method. Page 4 of 4
5 EVALUATION DAT-A 2011 Direct Antiglobulin Test INSTITUTION: ATTENTION: CAP NUMBER: Kit# 1 KIT INFORMATION: Kit ID: /31/2011 3/4/2011 Next Mailing Date: 9/26/2011 COPIED TO: LAP CAP LEGEND: Exception Reason Codes appearing in this evaluation: [11] = Unable to analyze (documentation to be provided by laboratory). [27] = Lack of participant or referee consensus. Reviewed By Date Page 1 of 2
6 DAT-A 2011 Direct Antiglobulin Test Test Method Specimen Your Result Intended Response Your Grade DAT Poly GEL TESTING DAT-01 NEGATIVE NEGATIVE /31/2011 3/4/2011 DAT-02 POSITIVE POSITIVE DAT-03 POSITIVE POSITIVE DAT IgG GEL TESTING DAT-01 NEGATIVE NEGATIVE DAT-02 NEGATIVE NEGATIVE DAT-03 POSITIVE POSITIVE DAT C3 GEL TESTING DAT-01 [11] DAT-02 DAT-03 [11] [11] DAT C3d GEL TESTING DAT-01 NEGATIVE NEGATIVE DAT-02 POSITIVE POSITIVE DAT-03 NEGATIVE [27] Page 2 of 2
7 Laboratory Results Summary Laboratory Test event CAP LAP Number Program Subscription Analyte Result ID Score» Syphilis CO1033AI Syphilis (SYPH435) 1 of 3 Print Date 2011/Mar/30 Problem Code Grade Actual Results Count Statistical Count Results Answer % PG: Method/Submethod Results Deadline Instrument 2011/Mar/15 Page Reagent 15 / % A Reactive ACC 30 1 Reactive 100% ID: Immunoassay/Chemiluminescent Abbott Architect ci8200 B Non Reactive ACC 30 1 Non Reactive 100% ID: Immunoassay/Chemiluminescent Abbott Architect ci8200 C Non Reactive ACC 30 1 Non Reactive 100% ID: Immunoassay/Chemiluminescent Abbott Architect ci8200 D Reactive ACC 30 1 Reactive 100% ID: Immunoassay/Chemiluminescent Abbott Architect ci8200 E Reactive ACC 30 1 Reactive 100% ID: Immunoassay/Chemiluminescent Abbott Architect ci8200 Syphilis - Titer Abbott Architect Abbott Architect Abbott Architect Abbott Architect Abbott Architect A Excused Abbott Architect ci8200 B Excused Abbott Architect ci8200 C Excused Abbott Architect ci8200 D Excused Abbott Architect ci8200 E Excused Abbott Architect ci8200 Grade: ACC - ; UNACC - Unacceptable; *ACC or *UNACC: Ungradable result due to either lack of peer group consensus or insufficient number of participants. As required by CLIA/CAP, you must verify the accuracy of these ungradable results.» This result is designated for regulatory purposes. Peer Group(PG) Codes: AR-all results; AU-all results in specific unit; ME-method; SM-submethod; RM-reagent manufacturer; RG-reagent group; RE-reagent; IM-instrument manufacturer; IG-instrument group; ID-instrument model Problem Codes: 1(Failure to participate); 2(Failure - Excl Requested); 11(Below Linear/Detection Limit); 22(Above Linear/Detection Limit); 33(Analyzer Out of Service); 66(Specimen Not Appropriate); 88(Testing Suspended During Test Event); DigitalPT Support from AccuTest Member_DigitalPT International EQA Collaboration support@digitalpt.com tel fax PO Box 999 Westford, MA, 01886, USA
8 Instituto Nacional de Salud REDES EN SALUD PÚBLICA INFORME DE RESULTADOS RELATORIO PEEDD EN INMUNOSEROLOGÍA Página 1 de 1 REG-R Versión Nº 00 PANEL INS TUBOS RESULTADO 1 Anti -HBc 2 Anti- Trypanosoma cruzi 3 AgHBs 4 Anti- HTLV I y II 5 Anti-VIH 6 No Reactivo 7 Anti- HTLV I y II 8 Sífilis 9 Anti- Trypanosoma cruzi 10 AgHBs 11 Sífilis 12 No Reactivo Los resultados falsos negativos y falsos reactivos deben servir como alerta para que sean revisadas todas las etapas referentes al uso de pipetas, puntas, diluyentes, calibración de lectores, entrenamiento y capacitación del personal técnico y profesional como también la revisión de controles internos utilizados. Estos resultados no deben ser atribuidos exclusivamente a la procedencia de las pruebas utilizadas por cada banco de sangre.
9 EVALUATION VM-B 2011 Viral Markers INSTITUTION: ATTENTION: CAP NUMBER: Kit# 1 KIT INFORMATION: Kit ID: /2011 6/12011 Next Mailing Date: 8/22/2011 COPIED TO: LAP CAP LEGEND: Exception Reason Codes appearing in this evaluation: <NONE> Reviewed By Date Page 1 of 4
10 VM-B 2011 Viral Markers Test Method Specimen Your Result Intended Response Your Grade HBsAg FLUORESCENT EIA VM /2011 6/12011 VM1-15 VM1-16 VM1-17 VM1-18 Anti-HBs FLUORESCENT EIA VM1-14 VM1-15 VM1-16 VM1-17 VM1-18 Page 2 of 4
11 VM-B 2011 Viral Markers Test Method Specimen Your Result Intended Response Your Grade Anti-HIV 1/2 RECOMBINANT EIA VM /2011 6/12011 VM1-15 VM1-16 VM1-17 VM1-18 Anti-HCV ABBOTT VM1-14 VM1-15 VM1-16 VM1-17 VM1-18 Page 3 of 4
12 VM-B 2011 Viral Markers /2011 6/12011 CAP #: Regulated Analyte Test Event Score % CAP Subspecialty : General Immunology Test Event Score % Test Event Score % Current Event Cumulative CLIA Performance '88 Performance Interpretation Interpretation Alpha-1-Antitrypsin S-C 5 / S-A Alpha-Fetoprotein K-C 5 / K-A Antinuclear Antibody S-C 5 / S-A Antistreptolysin O S-C 5 / S-A Anti-HIV VM-C 5 / VM-A VM-B Satisfactory Complement C3 S-C 0 / 5 0 S-A <4> Complement C4 S-C 0 / 5 0 S-A <4> Hepatitis (HBsAg) VM-C 5 / VM-A VM-B Satisfactory IgA S-C 4 / 5 80 S-A IgG S-C 5 / S-A IgE S-C 5 / S-A 4/ 5 80 IgM S-C 5 / S-A Rheumatoid Factor S-C 5 / S-A Successful Successful General Immunology 54/ / / Satisfactory Successful <4> Scorecard performance pending future evaluation or may not be applicable due to discontinued testing or use of a waived method. Page 4 of 4
13 Instituto Nacional de Salud PROCESO- REDES EN SALUD PÚBLICA INFORME DE RESULTADOS PEEDD EN INMUNOHEMATOLOGÍA Página 1 de 1 REG-R Versión Nº 00 CLAVE PANEL Lot x Exp: Lot x Sample o Muestra 1 Lot x Sample o Muestra 2 Grupo Sanguíneo A O Subgrupo A A1 Rh D Negativo Positivo Fenotipo Rh ccddee CcDEe Fenotipo K Negativo Negativo Rastreo de anticuerpos irregulares Positivo Negativo (RAI) Coombs Directo Negativo Positivo Identificación de Anticuerpos Lot: x Lot: x Sample o Muestra 1 Sample o Muestra2 Anticuerpo Anti- Jka Los resultados discordantes deben servir como alerta para que sean revisadas todas las etapas referentes al uso de pipetas, puntas, diluyentes, calibración de lectores, entrenamiento y capacitación del personal técnico y profesional como también la revisión de controles internos utilizados. Estos resultados no deben ser atribuidos exclusivamente a la procedencia de las pruebas utilizadas por cada banco de sangre o servicio de transfusión. La información de los resultados del PEED en inmunohematología es confidencial entre el INS, los bancos y servicios participantes.
14 EVALUATION VM-C 2011 Viral Markers INSTITUTION: ATTENTION: CAP NUMBER: Kit# 1 KIT INFORMATION: Kit ID: /22/ /6/2011 Next Mailing Date: 1/9/2012 COPIED TO: LAP CAP LEGEND: Exception Reason Codes appearing in this evaluation: <NONE> Reviewed By Date Page 1 of 4
15 VM-C 2011 Viral Markers Test Method Specimen Your Result Intended Response Your Grade HBsAg CHEMILUMINESCENCE VM /22/ /6/2011 VM1-28 VM1-29 VM1-30 VM1-31 Anti-HBs FLUORESCENT EIA VM1-27 VM1-28 VM1-29 VM1-30 VM1-31 Page 2 of 4
16 VM-C 2011 Viral Markers Test Method Specimen Your Result Intended Response Your Grade Anti-HIV 1/2 CHEMILUMINESCENCE VM /22/ /6/2011 VM1-28 VM1-29 VM1-30 VM1-31 Anti-HCV ABBOTT VM1-27 VM1-28 VM1-29 VM1-30 VM1-31 Page 3 of 4
17 VM-C 2011 Viral Markers /22/ /6/2011 CAP #: Regulated Analyte Test Event Score % CAP Subspecialty : General Immunology Test Event Score % Test Event Score % Current Event Cumulative CLIA Performance '88 Performance Interpretation Interpretation Alpha-1-Antitrypsin S-A 5 / S-B 4/ 5 80 Alpha-Fetoprotein K-A 5 / K-B Antinuclear Antibody S-A 5 / S-B Antistreptolysin O S-A 5 / S-B Anti-HIV VM-A 5 / VM-B VM-C Satisfactory Complement C3 S-A 5 / S-B Complement C4 S-A 5 / S-B Hepatitis (HBsAg) VM-A 5 / VM-B VM-C Satisfactory IgA S-A 5 / S-B IgG S-A 5 / S-B IgE S-A 4 / 5 80 S-B IgM S-A 5 / S-B Rheumatoid Factor S-A 5 / S-B Successful Successful General Immunology 64/ / / Satisfactory Successful <4> Scorecard performance pending future evaluation or may not be applicable due to discontinued testing or use of a waived method. Page 4 of 4
18 EVALUATION J-C 2011 Transfusion Medicine (Comp) INSTITUTION: ATTENTION: CAP NUMBER: Kit# 1 KIT INFORMATION: Kit ID: /6/ /7/2011 Next Mailing Date: 2/6/2012 COPIED TO: LAP CAP LEGEND: Exception Reason Codes appearing in this evaluation: [26] = Educational challenge. Reviewed By Date Page 1 of 6
19 J-C 2011 Transfusion Medicine (Comp) Test Method Specimen Your Result Intended Response Your Grade ABO Group J-15R GROUP O GROUP O /6/ /7/2011 J-16R GROUP A GROUP A GROUP A1 J-17R GROUP AB GROUP AB GROUP A1B J-18R GROUP O GROUP O J-19R GROUP O GROUP O Rh Type J-15R RH POSITIVE RH POSITIVE J-16R RH NEGATIVE RH NEGATIVE J-17R RH POSITIVE RH POSITIVE J-18R RH POSITIVE RH POSITIVE J-19R RH NEGATIVE RH NEGATIVE Antibody Detection J-15S ANTIBODY DETECTED ANTIBODY DETECTED J-16S ANTIBODY NOT DETECTED ANTIBODY NOT DETECTED J-17S ANTIBODY NOT DETECTED ANTIBODY NOT DETECTED J-18S ANTIBODY DETECTED ANTIBODY DETECTED J-19S ANTIBODY DETECTED ANTIBODY DETECTED Page 2 of 6
20 J-C 2011 Transfusion Medicine (Comp) Test Method Specimen Your Result Intended Response Your Grade Crossmatch Serology J-15S NEGATIVE NEGATIVE /6/ /7/2011 J-16S NEGATIVE NEGATIVE J-17S NEGATIVE NEGATIVE J-18S POSITIVE POSITIVE J-19S NEGATIVE NEGATIVE C Type J-20R POSITIVE 2+ [26] E Type J-20R NEGATIVE 0 [26] c Type J-20R NEGATIVE 0 [26] e Type J-20R POSITIVE 2+ [26] Other Antigens 1 J-20R Anti-K [26] NEGATIVE 0 Page 3 of 6
21 J-C 2011 Transfusion Medicine (Comp) /6/ /7/2011 CAP #: Regulated Analyte Test Event Score % Antibody Detection, Unexpected CAP Subspecialty : Unexpected Antibody Det Test Event Score % Test Event Score % J-A 5 / J-B J-C Current Event Cumulative CLIA Performance '88 Performance Interpretation Interpretation Satisfactory Successful Unexpected Antibody Det Satisfactory Successful Page 4 of 6
22 J-C 2011 Transfusion Medicine (Comp) /6/ /7/2011 ABO Group Rh (D) Type CAP #: Regulated Analyte Test Event Score % CAP Subspecialty : ABO Group/Rh Type Test Event Score % Test Event Score % J-A 5 / J-B J-C J-A 5 / J-B J-C Current Event Cumulative CLIA Performance '88 Performance Interpretation Interpretation Satisfactory Satisfactory Successful Successful ABO Group/Rh Type 10/ / / Satisfactory Successful Page 5 of 6
23 J-C 2011 Transfusion Medicine (Comp) /6/ /7/2011 CAP #: Regulated Analyte Test Event Score % Compatibility Testing CAP Subspecialty : Compatibility Testing Test Event Score % Test Event Score % J-A 5 / J-B J-C Current Event Cumulative CLIA Performance '88 Performance Interpretation Interpretation Satisfactory Successful Compatibility Testing Satisfactory Successful Page 6 of 6
Laboratory Results Summary
Laboratory Results Summary Laboratory CO1033AI Test event 2 of 3 CAP LAP Number 7181660 Page Print Date 9 / 10 2008/Jul/04 Program Syphilis (SYPH435) Results Deadline 2008/Jun/24 Subscription ID Analyte
DAT-B 2015 Direct Antiglobulin Test
EVALUATION DAT-B 2015 Direct Antiglobulin Test INSTITUTION: ATTENTION: CAP NUMBER: 7181660-01 Kit# 1 KIT INFORMATION: Kit ID: 28002258 10/12/2015 11/16/2015 Next Mailing Date: 2/22/2016 COPIED TO: LAP
PROFICIENCY TESTING. Clinical Laboratory Improvement Amendments (CLIA) DOs and DON Ts. Brochure # 8
Clinical Laboratory Improvement Amendments (CLIA) Brochure # 8 PROFICIENCY TESTING DOs and DON Ts NOTE: Congress passed the Clinical Laboratory Improvement Amendments (CLIA) in 1988 establishing quality
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 5 Immunology MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 6 Immunology 2016 MLE-M3 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 5 Immunology MLE-M2 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 7 Immunology 2017 MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 4 Immunology MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 3 Total Commitment to Education and Service Provided by ACP, Inc. Immunology MLE-M2 Table of Contents Evaluation Criteria...
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 7 Immunology 2017 MLE-M3 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...
Transfusion Medicine (Comprehensive, Limited) J, J1
www.cap.org Transfusion Medicine Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS). Transfusion Medicine (Comprehensive, Limited)
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 1 Total Commitment to Education and Service Provided by ACP, Inc. Immunology MLE M1 Table of Contents 2011 Evaluation Criteria...
CLIA APPROVED PROFICIENCY TESTING PROGRAMS ACCUTEST, INC. P.O. Box 999 Westford, Massachusetts (800)
ACCUTEST, INC. P.O. Box 999 Westford, Massachusetts 01886 (800) 665-2575 MICROBIOLOGY Bacteriology Aerobic Culture and Identification Antibiotic Susceptibility Testing Direct Antigen Detection Gram Stain
FINAL REPORT HBV Serology External Quality Assessment Scheme
FINAL REPORT HBV Serology External Quality Assessment Scheme Programme codes: HBVC4310, HBVC435 Panel ID: 2008/Mar/11 HBV Serology EQAS Panel ID 2008/Mar/11 Page 1 of 9 The NRL is a: NATA-accredited proficiency
The testing of Donated Blood and Components at NHSBT
The testing of Donated Blood and Components at NHSBT NHSBT is responsible for collecting all donated blood and platelets in England, then processing into components before issuing to client hospitals.
Proficiency Testing LABFACTS Requirements for good laboratory practice and COLA Laboratory Accreditation programs are underlined.
Proficiency Testing LABFACTS 8 INTRODUCTION Proficiency testing (PT) is an important aspect of an overall quality assurance program. PT serves as an external check to verify the accuracy of a 's results
Primary Sample Manual Infectious Serology Issue No Effective Date: 20/09/17 Page 1 of 15 EUROFINS BIOMNIS
Issue No. 2.02 Effective Date: 20/09/17 Page 1 of 15 Written / Revised By: Dr. Mike Louw, Medical Director Date: Reviewed By: Date: Dr. Sinead Kelly, Infectious Serology Consultant Authorised By: Jean-Sébastien
AccuSet HBV Worldwide Performance Panel
PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples
Transfusion Reactions. Directed by M-azad March 2012
Transfusion Reactions Directed by M-azad March 2012 Transfusion Reactions are Adverse reactions associated with the transfusion of blood and its components Transfusion reactions Non-threatening to fatal
q,a;e Fc ) ORIGINAL EVALUATION. FH9-B 2017 Hematology Auto Differentials, FH9
etiee INSTITUTION: ATTENTION: CAP NUMBER: KIT INFORMATION: COPIED TO: LKF Laboratorium fur Klinische Forschung GmbH Schwentinental GE 24223 Volker El-Samalouti PhD 7234136-01 Kit# 1 Kit ID: Kit Mailed:
REFERENCE LABORATORY. Regular Hours - Monday through Friday 8:00 AM to 4:00 PM. On-Call Staff - Evenings, Nights, Weekend and Holidays.
I. REFERENCE LABORATORY HOURS OF OPERATION: Regular Hours - Monday through Friday 8:00 AM to 4:00 PM. On-Call Staff - Evenings, Nights, Weekend and Holidays. All Reference Lab procedures are subject to
AccuVert HBV Seroconversion Panel PHM941(M) ( )
PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics
ORIGINAL EVALUATION. FH9-C 2017 Hematology Auto Differentials, FH9
ft Cit e * 4> ee e e e *111» * * PAT H 0 LO GI STS INSTITUTION: ATTENTION: CAP NUMBER: KIT INFORMATION: COPIED TO: LKF Laboratorium fur Klinische Forschung GmbH Schwentinental GE 24223 Volker El-Samalouti
Official Journal of the European Communities COMMISSION
16.5.2002 EN Official Journal of the European Communities L 131/17 COMMISSION COMMISSION DECISION of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under
Answering your daily challenges. in the ELISA technology I N FECTI OUS DISEASES. bioelisa
Answering your daily challenges in the ELISA technology I N FECTI OUS DISEASES bioelisa RETROVIRUS HIV is the cause of the most important global pandemic. Due to the lack of vaccination, early diagnosis
Confirmatory Testing Algorithm. Routine Donor Testing Algorithm
Confirmatory Testing Algorithm Blood Confirmatory ABO/Rh Beckman Coulter PK-ABO/Rh Immucor NEO ABO/Rh Immucor NEO ABO/Rh Immucor Manual ABO/Rh Typing Immucor Manual ABO/Rh Typing Discrepancy Resolution
Controls & Calibrators. Disease Quality Controls
Controls & Calibrators Infectious Disease Quality Controls Infectious Disease Quality Controls A broad selection of controls designed to monitor assay precision of hepatitis, retrovirus, sexually transmitted
PILOT STUDY OF ANTIGEN MATCHING FOR AUTOIMMUNE HEMOLYTIC ANEMIA
PILOT STUDY OF ANTIGEN MATCHING FOR AUTOIMMUNE HEMOLYTIC ANEMIA Sharon Rice & Fred Plapp Saint Luke s Hospital Kansas City, MO CENTRALIZED TRANSFUSION SERVICE Antibody identification Antibody titer Antigen
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More stringent - recommended Not legy binding and not recommended Tested pathogen Donor test/ technique
READ HIGHLIGHTED CHANGES
BIO-FLASH anti-hbs 3000-8581 100 tests The BIO-FLASH anti-hbs is a fully automated chemiluminescent simultaneous immunoassay for quantitative measurement of antibodies to Hepatitis B surface antigen (anti-hbs)
BLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine
BLOOD SAFETY STATUS IN INDONESIA Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine OUTLINE Background Blood services in Indonesia Regulation related to blood safety in Indonesia
Reflex Test Protocols
UCH Clinical Laboratory Reflex Test Protocols Blood Bank Prepare RBCs for Transfusion (aka Crossmatch) N/A No Antibody Screen ordered Antibody Screen Direct Antiglobulin Test (DAT) Polyspecific DAT Positive
Blood Screening Assays. CTS lab locations where assays are performed are indicated by alpha codes D, P, and T.
Blood Screening Assays CTS lab locations where assays are performed are indicated by alpha codes D, P, and T. D= performed in Dallas lab FEI: 3002580251 P= performed in Phoenix lab FEI: 3000204058 T= performed
Hepatitis A virus (HAV)
Volume 3, Issue 1 (Jan 2010) Editor s note Happy New Year and welcome to the first issue of QA Highlights of year 2010! In this issue, we are happy to bring to you Hepatitis Infection and Clinical Detection
Non-reproductive tissues and cells
Ministry of Health: Institute for Transplantation and Biomedicine / Colour key VIRAL HIV 1 and HIV 2 Hepatitis B Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More
Multichem Infectious Disease QC
Infectious Disease QC Contents Introduction....3 Quality Control in the Laboratory...4 Infectious Disease (ID) QC....5 Ready-to-use Concept....6 NRL...7 QConnect...8 IAMQC in Collaboration with QConnect....
This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2002D0364 EN 01.07.2012 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B COMMISSION DECISION of 7 May 2002 on common technical
Duration: 12 months May to April
SPECIALIST CERTIFICATE IN TRANSFUSION SCIENCE PRACTICE PROGRAMME OF STUDY OVERVIEW Example only Duration: 12 months May to April This document serves as a general programme overview only. To ensure you
QUALITY CONTROL Infectious Disease
QUALITY CONTROL Infectious Disease 1 Infectious Disease Quality Control The human based material used in the production of our Quality Controls is sourced from the Taiwan Blood Services Foundation (TBSF).
Reflex Test Protocols
Blood Bank Prepare RBCs for Transfusion (aka Crossmatch) N/A No Antibody Screen ordered Antibody Screen Direct Antiglobulin Test (DAT) Polyspecific DAT Positive polyspecific DAT IgG DAT, C3 DAT Fetal Cell
Within 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma
Test Name *Minimum Collection Tubes Sample Stability ABO/Rh Blood Typing 50 µl cells EDTA whole blood (lavender-top) Within 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma
FINAL REPORT HBV Serology External Quality Assessment Scheme
FINAL REPORT HBV Serology External Quality Assessment Scheme Programme codes: HBVC4310, HBVC435 Panel ID: 2008/Oct/28 HBV Serology EQAS Panel ID 2008/Oct/28 Page 1 of 11 The NRL is a: NATA-accredited proficiency
Disclosures. Relevant Financial Relationship(s): Nothing to Disclose. Off Label Usage: Nothing to Disclose 9/19/2017. Proficiency Testing
September 11, 2017 Teri Ross, Quality Specialist II Doreen Ryan, MA, MT; Quality Operations Supervisor Deborah J. Wells, MPA, MT(ASCP)SH, Quality Management Coordinator Disclosures Relevant Financial Relationship(s):
HIV-1 AccuVert Seroconversion Panel (PRB966) / Batch #
s/co c/ml DATA SHEET OVERVIEW 0600-0248 (PRB966) is a 10-member panel of undiluted, naturally occurring plasma samples. Panel members represent serial bleeds collected from a single patient over the course
: New graphic materials for bioelisa and bioblot product lines
1 NEWS BK NEWS # 385 /BE/ MKT DATE : 24-05-2016 TITLE : New graphic materials for bioelisa and bioblot product lines Dear colleagues, We are pleased to present the new materials for bioelisa and bioblot
The Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing
PERMISSON TO USE: Please note that, by making their presentations available on-line, primary authors have agreed to share their presentations. However, should you want to use some of the data or slides
Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016
New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new
MP Biomedicals Asia Pacific Pte. Ltd. (formerly Genelabs Diagnostics Pte. Ltd.)
Revision: 12 May 2005 1 WESTERN BLOT / IMMUNOBLOT HIV-1 BLOT Version 1.3* 11010-018 HIV-1 viral lysate Western Blot assay for the 11010-036 detection of antibodies to HIV-1 with serum 11010-108 108 strips
Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia
Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management
WHO Parvovirus B19 Genotype Panel
WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)
LIAISON Measles IgG The fully automated solution for quantitative antibody detection
LIAISON Measles IgG The fully automated solution for quantitative antibody detection FOR OUTSIDE THE US AND CANADA ONLY LIAISON Measles IgG Number of tests 100 Key assay features Method Assay range Solid
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC and its technical Directives (particularly 2006/17/EC) More stringent -legally binding, applies for all donations and all donor profiles
Parvovirus B19 Mixed Titer Performance Panel PVP201
A SERACARE PANEL PRODUCT INTENDED USE The is a panel of naturally occurring plasma specimens. This panel is intended for use by diagnostic manufacturers and clinical laboratories to evaluate their Parvovirus
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legally binding on national level More stringent testing - recommended on national level Not legally binding
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1
Innovation in Diagnostics. ToRCH. A complete line of kits for an accurate diagnosis INFECTIOUS ID DISEASES
Innovation in Diagnostics ToRCH A complete line of kits for an accurate diagnosis INFECTIOUS ID DISEASES EN TOXOPLASMOSIS Toxoplasmosis is a parasitic disease caused by with the obligate intracellular
NEWS BK NEWS # 378 /MKT DATE : TITLE. Dear colleagues,
1 NEWS BK NEWS # 378 /MKT DATE : 16022016 TITLE : New Bioelisa reagents Brochures Dear colleagues, We are pleased to present the new Bioelisa reagents Brochures, which are a very useful marketing and selling
See external label 2 C-8 C 96 tests Chemiluminescence. CMV IgM. Cat # Diluted samples, controls & calibrator 100 µl 30 minutes
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26
1 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Viral Load Quality Assessment Program Summary
HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27
1 The National Laboratory for HIV Reference Services is Accredited to ISO 15189 and ISO 17043 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology
Schedule of Accreditation
Schedule of Accreditation Organisation Name National Virus Reference Laboratory INAB Reg No 326MT Contact Name Eimear Malone Address University College Dublin, Belfield, Dublin Contact Phone No 01-7161319
Title:Evaluating HBsAg rapid tests performance in different biological samples from low- and high infection rates settings & populations
Author's response to reviews Title:Evaluating HBsAg rapid tests performance in different biological samples from low- and high infection rates settings & populations Authors: Helena M Cruz (h.medina@ioc.fiocruz.br)
We are pleased to present the new Leaflet bioelisa Menu and Instrumentation, with reference
NEWS BK NEWS# 390/ MKT DATE : 13-07-2016 TITLE : New Leaflet bioelisa Menu and Instrumentation Dear colleagues, We are pleased to present the new Leaflet bioelisa Menu and Instrumentation, with reference
The New Regulations - Special IVD Issues
The New Regulations - Special IVD Issues Dirk Stynen, Ph. D. President - Principal Consultant Qarad Geel, Belgium RMD Brussels October 2018 The IVD Regulation 2017/746 October 29, 2018 www.qarad.com 2
Impact of multi-dye multiplex technology on testing algorithm
Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT
Quality Control Solutions
Quality Control Solutions 1 CONTENT QCONNECT 3 ABOUT DIAMEX 6 ABOUT NRL 7 ABOUT EXACT DIAGNOSTICS 7 PRODUCTS 8 SEROLOGY MULTIMARKER RANGE 10 SEROLOGY SINGLE ANALYTE RANGE 16 NAT CONTROL RANGE 19 EXACT
HIV-1 Seroconversion Panel PRB973
A SERACARE PANEL PRODUCT INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratorians
AccuSet Autoimmune Performance Panel
PACKAGE INSERT 0840-0001 INTENDED USE The 0840-0001 is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot autoimmune related test
CARIBBEAN REGION EXTERNAL QUALITY ASSESSMENT SCHEME. Evaluation Booklet. Performance Evaluation Panel OPS0106 C. Coordination:
EXTERNAL QUALITY ASSESSMENT SCHEME Evaluation Booklet CARIBBEAN REGION Performance Evaluation Panel OPS0106 C Coordination: Fundação Pró-Sangue Hemocentro de São Paulo Pan American Health Organization
HIV-1 Seroconversion Panel PRB975
Seroconversion OVERVIEW is a five member HIV Seroconversion collected from a single donor over a 14 day period in 2002, prior to antibody seroconversion. -03 is a challenging sample for HIV RNA assays,
HTLV Serology Quality Assessment Program Summary for Panel HTLS Oct22
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLS425 2015Oct22
TRANSFUSION REACTIONS
14 TRANSFUSION REACTIONS 14.1 INTRODUCTION Transfusion of blood and blood products are reported to cause reactions during or after procedure specially in patients who receive multiple transfusions. These
EC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK
National Institute for Biological Standards and Control (NIBSC) EC Certificate - Full Quality Assurance System Approval Certificate Annex IV (excluding sections 4 and 6) of Council Directive 98/79/EC on
DS-EIA-ANTI-HIV-UNIF (Ab) I DS-EIA-ANTI-HIV-UNIF (Ab) I DS-EIA-ANTI-HIV-UNIF (Ab) I
* Sensitivity HIV DS-EIA-ANTI-HIV-UNIF (Ab) I-153 96 115 24 DS-EIA-ANTI-HIV-UNIF (Ab) I-150 192 115 24 DS-EIA-ANTI-HIV-UNIF (Ab) I-155 480 115 24 DS-EIA-HIV-AG-SCREEN I-1452 96 115 12 0.025 IU/ml DS-EIA-HIV-AGAB-SCREEN
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: SD BIOLINE HCV WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: SD BIOLINE HCV WHO reference number: PQDx 0257-012-00 SD BIOLINE HCV with product code 02FK10, manufactured by Standard Diagnostics,
The Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
AIHA The Laboratory Perspective on Testing. Tom Bullock Joint UK NEQAS (BTLP) & BBTS BBT SIG Annual Meeting 20 th November 2018
AIHA The Laboratory Perspective on Testing Tom Bullock Joint UK NEQAS (BTLP) & BBTS BBT SIG Annual Meeting 20 th November 2018 Auto Immune Haemolytic Anaemia (AIHA) BSH guideline (Hill et al. 2017): AIHA
Khalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia
1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding on national level More stringent - recommended on national level Not legy binding and not recommended on
2014 Continuing Compliance Master Series Best Practices in Alternative Assessment of Performance
2014 Continuing Compliance Master Series Best Practices in Alternative Assessment of Performance Brad S. Karon, MD, PhD, FCAP November 19, 2014 www.cap.org Today s Presenter Brad S. Karon, MD, PhD, FCAP
Structure and duties of Blood service
NATIONAL CENTER FOR TRANSFUSION MEDICINE Prevalence of infectious diseases among Mongolian blood donors Namjil Erdenebayar General director of The National Center for Transfusion Medicine, Mongolia NCTM,
AccuVert HIV-1 Seroconversion Panel PRB974 ( )
PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers
Robert G. Gish MD UC San Diego
Robert G. Gish MD UC San Diego The Pipeline of HIV-Related Point-Of- Care Tests is Growing Viral detection Examples: 2012 2013 2014 2015 2016 2017 CD4 test Examples: 2009 2010 2011 2012 2013 0 2014 Evidence
INSTRUCTIONS FOR BLOOD BANK INSPECTION CHECKLIST AND REPORT CMS-282
Note to Surveyors: INSTRUCTIONS FOR BLOOD BANK INSPECTION CHECKLIST AND REPORT CMS-282 This form consists of portions of the FDA-2609. These portions are the only parts of the FDA-2609 that have been approved
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of Accreditation 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK National Infection Service, Public Health England Colindale 61 Colindale Avenue London NW9 5EQ Contact: Dr Sanjiv
WHO Prequalification of Diagnostics Programme PUBLIC REPORT
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: ABON HIV 1/2/O Tri-Line Human Immunodeficiency Virus Rapid Test Device Number: PQDx 0141-051-00 Abstract ABON HIV 1/2/O Tri-Line Human
AccuSet HCV Performance Panel
Signal to cutoff (s/co) DATA SHEET OVERVIEW AccuSet HCV (0810-0204) is a 25-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members
PROFICIENCY TESTING POLICY
Supersedes Prepared by: APPROVALS in this section Approved by: Date: Laboratory Director RECORD OF REVIEWS Date Signature Title Procedural Changes/Review VERSION HISTORY Revision # 0 Section #/Changes
Infectious Disease Controls for Serology Testing
Infectious Disease Controls Infectious Disease Controls for Serology Testing A comprehensive guide for monitoring testing for Hepatitis, Retrovirus, Sexually Transmitted and Congenital Diseases Table of
2019 HIV Diagnostics Conference March 27, 2019
2019 HIV Diagnostics Conference March 27, 2019 Performance of the Syphilis Reverse Algorithm Using the Abbott Architect Syphilis TP (ASTP) and its Role in a Blended Diagnostic Application in Florida s
OIE Reference Laboratory Reports Activities
OIE Reference Laboratory Reports Activities Activities in 2016 This report has been submitted : 2017-01-05 21:59:05 Name of disease (or topic) for which you are a designated OIE Reference Laboratory: Avian
Direct Antiglobulin Test (DAT)
Exercise 8 Direct Antiglobulin Test (DAT) Objectives 1. State the purpose for performing the DAT. 2. State what a positive DAT indicates. 3. List the reagents which are used for performing the DAT. 4.
Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
PRODUCT CATALOGUE YOUR GLOBAL PARTNER IN DIAGNOSTICS
PRODUCT CATALOGUE YOUR GLOBAL PARTNER IN DIAGNOSTICS WELCOME Omega Diagnostics Ltd is a wholly owned subsidiary of Omega Diagnostics Group PLC. Formed in 1987, Omega is one of the UK s leading manufacturers
ELISA kits for infections (HIV; Hepatitis A, B, C, D, E; Syphilis, ToRCH and others), hormone pathologies and tumor markers.
DSI S.r.l. DSI S.r.l. is one of the European leaders in the field of immunodiagnostic tests manufacturing. We are a research-focused company with the long-term microbiological scientific traditions. Our
Tel: Tel: Web: CODE DESCRIPTION UNITS
New Instruments MICROPLATE ANALYZERS DESCRIPTION UNITS MDIMOD2 Modulus2 2-4 Microplate Analyzer 1 Refurbished Instruments MICROPLATE ANALYZERS DESCRIPTION UNITS MDINXGMI Refurbished Nexgen 4-Microplate
SOLE-SOURCE DETERMINATION
SOLE-SOURCE DETERMINATION The Purchasing Division has been requested to approve a sole source purchase for the commodity or service described below. Pursuant to West Virginia Code 5A-3-10c, the Purchasing
Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory
Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory Describe the challenges in syphilis diagnostics Present two testing algorithms Non-treponemal test as initial screen Treponemal
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK West of Scotland Specialist Virology Centre New Lister Building Level 5 Glasgow Royal Infirmary 10-16 Alexandra Parade Glasgow G31 2ER Contact: